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christoph.schmid@usz.chAbstractAcromegaly is characterized by excessively high GH and IGF1 levels. Recent data suggest
that soluble Klotho (sKlotho) is also elevated in patients with active acromegaly. sKlotho
decreases towards normal following removal of the GH-producing pituitary adenoma.
The Klotho gene was identified in mice following its accidental disruption by ectopic DNA.
It is an ageing suppressor gene of restricted expression (mainly in kidneys, brain, and
parathyroid and pituitary glands) encoding a transmembrane protein, mKlotho. mKlotho
serves as a co-receptor in fibroblast growth factor 23 (FGF23) signalling. FGF23 promotes
urinary phosphate excretion and inhibits the synthesis of calcitriol. The ectodomain of
mKlotho is enzymatically released to result in a humoral factor, sKlotho, which exerts
systemic effects (on ion channels and signalling pathways), possibly by working as an
enzyme that modifies glycans of cell surface glycoproteins. GH enhances renal phosphate
reabsorption and calcitriol production, i.e. exerts effects in the proximal tubule opposing
those attributed to mKlotho, and attenuates calciuria in the distal tubule similar to sKlotho.
sKlotho can be measured in extracellular fluids (serum, urine and cerebrospinal fluid (CSF))
by an ELISA. In line with predominant expression of Klotho in kidneys and choroid plexus,
concentrations of sKlotho are particularly high in urine and CSF. Determination of sKlotho
in serum and urine (both presumably reflecting GH action on the kidneys) could be
used as a supplementary tool in the diagnosis and follow-up of patients with acromegaly.
The question arises whether GH exerts selected actions via modifying activities of Klotho.Key Words
" Klotho
" growth hormone
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" FGF23
" IGF1Journal of Endocrinology
(2013) 219, R37–R57IntroductionThis review on growth hormone (GH) and Klotho covers
novel findings on a well-known hormone, the first to be
extracted and characterized from the pituitary gland, and
a more recently, accidentally discovered multifunctional
protein. To enhance comprehension of the relationship
between the two, we also discuss insulin-like growth
factor 1 (IGF1), the first growth factor isolated and
characterized from human serum, and fibroblast growth
factor 23 (FGF23), currently the last member of the
FGF family to be cloned. IGF1 is important for theapprehension of GH actions, and FGF23 is important for
the understanding of the action of Klotho. These two
growth factors illustrate the continuum between locally
acting growth factors and systemically active hormones.
Klotho works both locally and as a circulating humoral
factor. Klotho was recently renamed a-Klotho, after the
discovery of new Klotho family members; however,
b-Klotho will be mentioned only briefly, although GH
probably interacts with both a- and b-Klotho endocrine
communication lines.
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Acromegaly is a characteristic and disfiguring disease,
described as a clinical entity in the late 19th century,
which was later found to be caused by an eosinophil
pituitary adenoma. GH excess produced by an adenoma of
the pituitary gland is the major cause for acromegaly with
an incidence of approximately four cases per 1 million
persons per year. Clinical features develop insidiously and
progressively over many years. It includes changes in the
patient’s appearance, mainly soft tissue swelling and
cartilage and bone growth, resulting in typical acral
enlargement and coarse facial features. Thus, with
increasing typical signs and symptoms, diagnosis of
acromegaly is generally straightforward. However, due to
limited awareness of a rare disease, the correct diagnosis is
often considerably delayed and is therefore associated
with increased mortality even after curative therapy. For
patients with acromegaly, (transsphenoidal) surgery
remains the most promising therapeutic option, as it
offers the best chance for long-term cure and restoration of
pituitary function, including normalized GH secretion.
Currently, GH and IGF1 (a marker and mediator of GH
actions) are the classical biochemical markers of disease
activity in acromegaly. Increased levels of GH (i.e. not
suppressible to a nadir !1 mg/l during oral glucose
tolerance testing, or!0.3 mg/l, with more modern assays)
and IGF1 on blood testing support the diagnosis. Likewise,
to define cure, biochemical assessment is superior to MRI,
as tiny tumour remnants are not reliably depicted.
The healthy human pituitary contains several milli-
grams of GH. Pituitary extracts were found to cause
gigantism and pituitary hormones were found to be
diabetogenic. GH was first isolated in 1944. In 1957,
extraction of human GH from cadaver pituitaries suc-
ceeded, and in 1958, use of the extracted hormone to treat
pituitary dwarfs was reported. During childhood and
adolescence, when the epiphyseal lines have not fused,
GH stimulates longitudinal bone growth, and GH excess
from adenomas causes gigantism. In 1963, a RIA for GH was
developed, and by 1970, Li succeeded with determination
of the amino acid sequence and synthesis of GH. In 1985,
several cases of Jakob Creutzfeldt disease were reported,
and in the same year, recombinant human GH (rhGH) was
introduced for therapeutical use in children. GH is effective
in promoting growth of children with GH deficiency.
However, in the rare condition of GH insensitivity (type
Laron-Dwarfism), e.g. due to GH receptor (GHR) deficiency
(‘GHR-k.o.’), endogenous GH is high, and there is no
response to rhGH administration (Godowski et al. 1989).http://joe.endocrinology-journals.org  2013 Society for Endocrinology
DOI: 10.1530/JOE-13-0285 Printed in Great BritainThe wide availability of rhGH led to an increasing
number of studies in adults with hypopituitarism includ-
ing GH deficiency, and rhGH was reimbursed in 1996 for
use in adulthood. It has never been established that
isolated GH deficiency is associated with an increase in
morbidity and mortality; however, GH excess is related to
an increase in standard mortality rate.
GH is a single-chain polypeptide hormone (with two
disulphide bridges) synthesized, stored and secreted by the
somatotropic cells of the pituitary gland. GH consists of
191 amino acids, corresponding to the main circulating
form, which is 22 kDa in size and mainly bound to a GH-
binding protein (GHBP); the latter is derived from the GHR
by proteolytic cleavage. GH is secreted in a pulsatile
manner, mainly regulated by hypothalamic neuroendo-
crine mediators such as (inhibitory) somatostatin and
GH-releasing hormone, but also by signals from the
periphery such as (stimulatory) ghrelin and by feedback
inhibition via IGF1. The effects of GH are mediated by the
GHR. The human GHR gene was characterized by Wood
and colleagues in 1989 (Godowski et al. 1989). It is a
member of a large cytokine receptor family that also
includes erythropoietin and IL6. Activation of the GHR by
GH binding results in a conformational change of the
receptor as well as in an activation of a JAK system and
several downstream pathways, including STAT members
and MAPK. The extracellular fragment of the GHR is
cleaved from the cell surface and circulates as a GHBP.
GHBP prolongs plasma half-life of circulating GH, which is
estimated to be 2–5 min in the free form and 15–20 min in
the GHBP-bound form. GH is cleared from the circulation
via tissues that are also responsive to the hormone,
especially liver and kidneys.Activities of GH and IGF1
GH promotes (longitudinal bone) growth. It is anabolic,
increasing protein synthesis and net nitrogen retention,
and insulin is required for these effects. Some of the
properties of GH have been fairly well characterized,
e.g. on liver (increasing IGF1 production, synergistic
with insulin), on cartilage (growth) and on adipose tissue
(increasing lipolysis, antagonistic to insulin). However,
other actions of GH are still poorly understood, such
as the action on kidney function and phosphate
homoeostasis, or on endothelial function. Some of the
effects of GH are direct, e.g. on liver, adipose tissue and
striated muscle (i.e. classical insulin target tissues)
whereas others are mediated by IGF1 (and possibly
other mediators).Published by Bioscientifica Ltd.
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IGFs were discovered by three independent groups
(Salmon & Daughaday 1957, Froesch et al. 1963, Pierson
& Temin 1972), which were interested in biological
activities exerted by serum: i) stimulation of proteoglycan
synthesis (sulphate incorporation) in cartilage by
a GH-dependent ‘sulfation factor’ (somatomedin),
ii) insulin-like activity (non-suppressible by anti-insulin
antibodies) on adipose tissue and iii) mitogenic activity on
fibroblasts in vitro (multiplication-stimulating activity
(MSA)). IGF1 works as a somatomedin in animals and in
man (Schoenle et al. 1982, Laron et al. 1992).
Tests assessing the biological activities of GH and
insulin were difficult 60 years ago and required in vivo
bioassays (measuring the increase in body weight or in
epiphyseal width in hypophysectomized rats, or the
extent of blood sugar decrease in experimental animals);
in search of improved methods (before RIAs were
introduced), interesting discoveries were made.
Serum stimulates incorporation of 35SO4 into cartilage
in vitro. In 1957, Salmon and Daughaday reported that
serum of hypophysectomized rats lacked such an activity.
It could be reconstituted by administration of GH to
hypophysectomized rats, but not by addition of GH to
cartilage cultured in serum of hypophysectomized rats.
These observations led to the concept that GH does not
stimulate growth directly, but rather induces formation of
factors that mediate action of GH. These factors were
first called sulfation factors and later somatomedins;
a GH-dependent plasma factor stimulates the incorpo-
ration of sulphate into chondroitin sulphate in cartilage
(Salmon & Daughaday 1957, Daughaday et al. 1972).
Serum contains insulin-like activity. Froesch et al.
observed that most of the insulin-like activity in serum
could not be suppressed by the addition of antiserum
neutralizing insulin to the incubation medium. Therefore,
‘non-suppressible insulin-like activity (NSILA)’ was
different from insulin but could mimic its effects on
adipose tissue (Froesch et al. 1963). Later, molecules
(7.6 kDa in size) responsible for this insulin-like activity
were purified from serum and characterized (Rinderknecht
& Humbel 1978). The designation IGFs appeared justified
as IGFs are functionally and structurally closely related to
insulin. As the C-domain of IGFs is not removed during
prohormone processing, mature IGF peptides are single-
chain polypeptides. IGF1 consists of 70 amino acids and
displays 43% sequence identity to the insulin A- and
B-chain (Rinderknecht & Humbel 1978). IGFs bound to
IGF binding proteins (IGFBPs) cannot interact with insulinhttp://joe.endocrinology-journals.org  2013 Society for Endocrinology
DOI: 10.1530/JOE-13-0285 Printed in Great Britainreceptors; moreover, the affinity of IGFs to insulin
receptors is low.
Serum provides components required for optimal
growth of most cells in culture, including growth factors.
Factors could be extracted from serum with MSA, i.e.
factors that stimulate replication of cells in culture (Pierson
& Temin 1972). Subsequently, it was found that MSA was
also produced by cultured liver cells (Dulak & Temin 1973).
IGFs (IGF1 and IGF2) signal through type 1 IGF
receptors. Insulin and IGF have their own distinct cell
surface receptors whose structures have been deduced
from analysis of isolated cDNA clones. Type 1 IGF and
insulin receptor are homologous (Ullrich et al. 1986);
both consist of a2b2 ‘hetero-tetrameric’ structures. The
a-subunits lie entirely extracellular and contain a ligand-
binding domain, while the b-subunits are transmembrane
polypeptides that contain a tyrosine kinase domain in
their intracellular portion. Signal transduction by type 1
and insulin receptors involves autophosphorylation at
tyrosine residues and phosphorylation of other substrates.
Radiolabelled IGFs had been used to characterize
specific IGF binding sites (receptors) on cells. In addition,
they allowed the discovery of specific IGFBPs in extracellu-
lar fluids. IGFBPs in the strict sense are entirely unrelated to
IGF receptors and bind IGFs with comparable or even
higher affinity than the type 1 IGF receptor. IGFBP3 is by
far the most abundant IGFBP in adult human serum, and
its production (like that of IGF1) is dependent on GH both
in vivo and in vitro. Intact IGFBP3 prevents access of IGF1 to
its receptors, but proteolysis of IGFBP3 activates IGF1
signalling (Schmid et al. 1991). GH (but not IGF1) induces
an IGFBP3-proteolytic activity (Rutishauser et al. 1993).
IGFBPs appear to affect distribution volumes and half-
lives of IGFs; they contribute to the large pool of IGFs
present in most extracellular spaces, and they modify their
biological activity. IGFBP3 serves as the major circulating
carrier of IGFs, most of which are associated with a
GH-dependent ternary complex of 140 kDa, comprising
an acid-labile 85 kDa glycoprotein, IGFBP3, and IGF1 or
IGF2. The apparent half-life of IGFs is about 10 min in
their free form and 10–15 h when in the ternary complex;
the large molecular weight complex accounts for the slow
turnover of serum IGFs (Guler et al. 1989).
IGF1 is produced continuously, especially in the liver
that is estimated to be is responsible for 70–80% of
circulating IGF1. Apart from the ‘endocrine’ IGFs, IGFs
are also produced in most tissues where they can act in a
paracrine or autocrine manner. Serum IGF1 is a good
hepatic marker of GH action. Owing to its long plasma
half-life, levels are fairly stable throughout the day,Published by Bioscientifica Ltd.
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not critical.
Until now, GH and especially GH activity, as reflected
(in part) by IGF1 concentrations, have been the ‘classical’
biomarkers for diagnosing and monitoring disease activity
during the treatment of patients with acromegaly. Their
normalization has been linked to decreased mortality.
However, it has been recognized that both parameters
entail various shortcomings, both analytical and biologi-
cal (Clemmons 2011). GH levels are age dependent, and
serum levels of IGF1 are influenced not only by GH status
but also by age, gender (oestrogens), race, liver function,
nutritional status, portal insulin, thyroid hormones and
by concomitant inflammatory disease. Unfortunately,
measuring IGF1 remains notoriously difficult, especially
since IGFBPs interfere with immunoassay analysis. For the
classical and time-consuming RIAs, IGF carrier proteins are
removed before the samples are incubated with the
antibodies (Zapf et al. 1980, 1981). Ideally, IGF1 should
normalize and glucose-suppressed GH should be low after
surgery for acromegaly. Most often, 1 mg/l (or lower) has
been used as a cut-off value (Giustina et al. 2010).Activities of FGF23
FGF23 may be most easily understood by the recognition
of tumours by which it is secreted in excessive amounts.
Similar to acromegaly, tumour-induced osteomalacia
(TIO) is an acquired condition that can resolve after
successful removal of the tumour, the source of excessive
FGF23. In 1957, Prader reported the case of an 111⁄2 -year-
old girl who presented with an acquired disorder of
hypophosphataemia, renal phosphate wasting and rickets.
He attributed the phenotype of the disease to a circulating
factor, a ‘rachitogenic substance’ secreted by the tumour
causing renal phosphate wasting (‘phosphate diabetes’), as
it disappeared after surgical excision of a benign mixed
connective tissue tumour from the rib (Prader et al. 1959).
The phenotype described corresponds to what we would
nowadays designate a case of FGF23-mediated TIO. FGF23
was later cloned as a causative factor from tumours that
result in osteomalacia (Shimada et al. 2001).
Two other groups, independently, had previously
cloned FGF23, by homology as an additional FGF family
member, preferentially expressed in the ventrolateral
thalamic nucleus of the brain, and by genetic analysis of
autosomal dominant hypophosphataemic rickets (ADHR;
ADHR Consortium 2000, Yamashita et al. 2000).
Shimada reported in 2004 that overexpression of
FGF23 in rodents essentially replicated the phenotype ofhttp://joe.endocrinology-journals.org  2013 Society for Endocrinology
DOI: 10.1530/JOE-13-0285 Printed in Great BritainTIO and ADHR. Independent groups confirmed that
FGF23 overexpression in transgenic animals or its
administration to rodents resulted in renal phosphate
loss, hypophosphataemia, impaired production of
1,25-(OH)2D and rickets (Bai et al. 2004, Larsson et al.
2004, Shimada et al. 2004c).
FGF23, a 32 kDa glycoprotein with very weak heparin-
binding affinity, is produced mainly in bone by osteo-
blasts/osteocytes; its production is stimulated by
decreased glomerular filtration rate (GFR)/low nephron
number as with chronic kidney disease (CKD) and ageing
and dietary phosphate overload. The 24 amino acid
hydrophobic signal sequence is removed and the protein
O-glycosylated by GALNT3 to produce the mature,
biologically active 25FGF23251 form in the circulation,
with an estimated half-life of about 50 min (Khosravi et al.
2007). FGF23 acts predominantly on kidneys to decrease
sodium (Na)-dependent phosphate transporters NaPi2a
and NaPi2c (SLC34a1 and SLC34a3) activity and thereby
increase phosphate excretion (‘phosphatonin’) (Shimada
et al. 2004c, Segawa et al. 2007, Gattineni et al. 2009).
It inhibits vitamin D 1a-hydroxylase (CYP27B1) and calci-
triol generation, and it enhances 24a-hydroxylase
(CYP24A1) and calcitriol degradation (Saito et al. 2003,
Shimada et al. 2004a). Therefore, excessive FGF23 pro-
duction (by tumours) or inadequate inactivation (in
ADHR) of FGF23 results in hypophosphataemia and
rickets (in children) or osteomalacia (in adults). This
happens due to renal phosphate loss (‘acquired phosphate
diabetes’), inhibition of vitamin D 1a-hydroxylase
(impaired calcitriol production) and disturbed mineral-
ization. In patients with progressive fatigue, muscle
weakness and bone pain, persistent hypophosphataemia
due to renal phosphate wasting and an inappropriately
low 1,25-(OH)2 D level are the biochemical hallmarks of
TIO (Bauer et al. 2010).
To understand the physiological roles of FGF23, mice
lacking FGF23 were generated by targeted gene disruption.
Defective production results in hyperphosphataemia and
activation of vitamin D 1a-hydroxylase, severe calcifica-
tions (subcutaneous, periarticular, kidneys, lungs and
vessels) and premature ageing. These Fgf23K/K mice
have, reminiscent of KlothoK/K mice, hyperphosphat-
aemia and extremely high serum calcitriol levels (Yoshida
et al. 2002, Shimada et al. 2004b). It was realized that
Fgf23K/Kmice (lacking the hormone) and KlothoK/Kmice
(lacking functioning receptors) had similar phenotypes
(see below).
FGFs signal through tyrosine kinase receptors and
ERK. Among the 22 FGF members, most act in anPublished by Bioscientifica Ltd.
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Review C SCHMID and others Growth hormone and Klotho 219 :2 R41autocrine or paracrine fashion. The FGF19 (endocrine)
subfamily includes FGF15 (in mice)/FGF19 (in humans),
FGF21 and FGF23 (Itoh & Ornitz 2011). These hormone-
like FGFs appear to be vertebrate specific and characteristi-
cally lack a heparin-binding domain. Therefore, they are
not retained by the nearby extracellular matrix and reach
the circulation. Moreover, endocrine FGFs do not require
heparan sulphate proteoglycans for efficient FGFR tyrosine
kinase activation; instead, they need transmembrane
Klotho(s) (mKlotho) as co-receptors (see section Klotho,
a transmembrane co-receptor and a multifunctional
humoral factor in extracellular spaces). FGF15/FGF19 is
mainly produced by the small intestine and predomi-
nantly targets the liver (FGFR4 and b-Klotho coexpression)
to regulate cholesterol and (suppress) bile acid synthesis.
FGF21 is mainly secreted from the liver and predomi-
nantly acts on white adipose tissue (FGFR1c and b-Klotho
coexpression) to regulate glucose and lipid metabolism.
This corresponds to FGF23, which is mainly produced by
bone and predominantly targets the kidneys to regulate
phosphate and vitamin D metabolism. b-Klotho belongs
to the receptor complex of the former two endocrine FGFs
and a-Klotho to the receptor complex of FGF23. In the
kidneys, FGFR1 may be the most relevant receptor to
mediate FGF23 actions (Gattineni et al. 2009). An
activating mutation of FGF1R has been reported to cause
osteoglophonic dysplasia and hypophosphataemia (White
et al. 2005). Antibodies activating FGFR1 also cause
hypophosphataemia (Wu et al. 2013).Klotho, a transmembrane co-receptor and
a multifunctional humoral factor in
extracellular spaces
While studying the phenotype of transgenic mice over-
expressing the rabbit type I sodium proton exchanger,
insertion of ectopic DNA happened to occur into the
5 0 promoter region of the a-Klotho gene; a-Klotho protein
was hardly expressed. The Klotho gene was thereby
identified serendipitously in this mouse model in 1997
after recognition that its disruption caused a phenotype of
accelerated ageing (Kuro-o et al. 1997). Later, it was found
that ageing suppression and lifespan extension were
achievable in mice by overexpression of Klotho; these
mice lived about 20% longer than WT mice and were more
resistant to oxidative stress (Kurosu et al. 2005). The name
Klotho stems from the goddess of fate, which is ‘spinning
the thread of life’ in Greek mythology. Mice with deficient
Klotho expression have a syndrome that resembles
human ageing, including shorter lifespan (on average,http://joe.endocrinology-journals.org  2013 Society for Endocrinology
DOI: 10.1530/JOE-13-0285 Printed in Great Britainonly 2 months instead of 2–3 years as for WT mice),
premature skin atrophy, osteopenia/osteoporosis, dys-
function of the pituitary gland (GH deficiency), growth
retardation, hypogonadotropic hypogonadism (inferti-
lity), atrophy of genital organs, thymus and muscle,
arteriosclerosis, ectopic (soft tissue and media-) calcifica-
tions, pulmonary emphysema and neurodegenerative
disorders (hypokinesis, gait disturbances and hearing
disorder). Klotho-deficient mice were subsequently
characterized in more detail; e.g. the brain phenotype
(distinct from the aged human brain with senile plaque
deposition) includes memory retention deficits, a
reduction in synapses in the hippocampus, disturbed
axonal transport and hippocampus degeneration and
impaired myelin production in specific areas of the brain
(Nagai et al. 2003, Li et al. 2004, Shiozaki et al. 2008, Chen
et al. 2013a). A recent study suggested that decreased
activation of JAK2/STAT3 signalling and cholinergic
pathways in hippocampus may play an important role
in cognitive impairment observed in Klotho mutant
mice (Park et al. 2013). Biochemically, Klotho deficiency
results in hyperphosphataemia with increased 1,25-(OH)2
vitamin D3 and high FGF23 in keeping with FGF23
resistance, moreover in hypoglycaemia with low insulin
(insulin hypersensitivity).
The Klotho gene product was proposed to function as a
part of a signalling pathway that regulates ageing in vivo
and morbidity in age-related diseases. The Klotho mouse
created by unintentional insertion is not a strictly null
strain, but a KlothoK/K mouse was later intentionally
generated, and this ‘classical’ knockout mouse was found
to exhibit essentially the same phenotype as the original
Klotho mouse, including hyperphosphataemia and dis-
turbed vitamin D regulation (Tsujikawa et al. 2003). Over
the past decade, several aspects reported in the original
1997 paper were described in more detail, including
neurodegeneration, hearing loss, sarcopenia, ageing lung/
emphysema and arteriosclerosis. However, discussing all of
them would be beyond the scope of the current review.
Several excellent reviews discuss specific aspects of Klotho
in more detail (Nabeshima & Imura 2008, Kuro-o 2010,
Manya et al. 2010, Martin et al. 2012, Hu et al. 2013).
The Klotho gene encodes a single-pass type I trans-
membrane protein (1014 amino acids in the mouse and
1012 in humans) with a short cytoplasmic domain and an
extracellular domain composed of two b-galactosidase/
glycosidase-like tandem repeats (KL1 and KL2) with
b-glucuronidase and sialidase activity. It is predominantly
expressed in kidneys, brain (choroid plexus (CP), neurons
in hippocampus, Purkinje cells and inner ear), thePublished by Bioscientifica Ltd.
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Figure 1
Transmembrane and soluble a-Klotho. A plasma cell membrane is shown
into which mKlotho (single-pass transmembrane, very short cytoplasmic
tail) is inserted. mKlotho associates with an FGFR; the latter can transmit
(FGF23-induced) signals through its tyrosine kinase domains and ERK
activation. sKotho can be derived from mKlotho when its large
extracellular part (130 kDa) is clipped off by enzymes; apart from this large
sKlotho form, there may be a smaller, directly secreted sKlotho form
(65 kDa), resulting from differential splicing. mKlotho (cofactor for FGF23
binding to FGFR) expression is restricted to a limited number of tissues
while sKlotho is present in most extracellular spaces and can regulate many
processes throughout the body, including calcium handling, nitric oxide
synthesis, insulin and (e.g. insulin-like) growth factor signalling,
as discussed in the text.
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(pituitary, parathyroid and pancreas) and reproductive
organs (gonads and placenta) (Kuro-o et al. 1997, Kato
et al. 2000, Li et al. 2004, Takeshita et al. 2004, German
et al. 2012). Although primarily in distal convoluted
tubules, Klotho is expressed in all tubular segments
along the nephron (Hu et al. 2010, Zhou et al. 2013).
More details on the mouse Klotho gene and the identifi-
cation of the human (96% homology) as well as the rat
Klotho gene were reported 1 year later (Matsumura et al.
1998, Ohyama et al. 1998, Shiraki-Iida et al. 1998); two
distinct transcripts encoding membrane and secreted
Klotho protein were characterized. Klotho has been
identified not only in the zebrafish, Danio rerio, but two
Klotho-like genes, klo1 and klo2, have also been identified
in the nematode Caenorhabditis elegans (Polanska et al.
2011, Sugano & Lardelli 2011, Mangos et al. 2012). The
corresponding KLO1 and KLO2 proteins lack a trans-
membrane domain. The ancestral ‘truncated’ Klotho
forms in nematodes contain only one KL domain and
lack the second internal repeat (whereas the full-length
transmembrane vertebral Klothos are composed of two KL
domains). Therefore, they correspond more closely to the
alternatively spliced form for the shorter, directly secreted
isoform in men (Polanska et al. 2011).
The function of mKlotho protein remained an enigma
for years. It was first recognized that FGF23 deficiency and
Klotho deficiency (with FGF23 resistance) result in closely
resembling phenotypes, namely with hyperphosphat-
aemia by up-regulated NaPi cotransporters, grossly
elevated 1,25-(OH)2 D3, due to up-regulated 1a-vitamin
D hydroxylase, vascular calcification and premature
ageing (Yoshida et al. 2002). In 2006, two independent
groups reported that mKlotho served as a co-receptor for
FGF23 (Kurosu et al. 2006, Urakawa et al. 2006). mKlotho
forms a constitutive binary complex with the FGFR1c to
create a de novo high-affinity binding site for FGF23. This
Klotho–FGFR complex binds to FGF23 with much higher
affinity than FGFR or Klotho alone; Klotho greatly
enhances the ability of FGF23 to induce phosphorylation
of FGFR substrate and ERK and is thus considered an
essential cofactor for activation of FGF23 signalling by
FGFR23. FGF23 elicits ERK phosphorylation and up-
regulation of the expression of early growth-responsive
(Egr) mRNA in Klotho-expressing tissues and cells, in
the kidneys, parathyroids and pituitary, but not in liver,
heart, bone and arterial walls (Kurosu et al. 2006, Urakawa
et al. 2006, Ben-Dov et al. 2007, Krajisnik et al. 2007,
Andrukhova et al. 2012, Lindberg et al. 2013). These (renal)
FGF23 activity-enhancing properties of mKlotho arehttp://joe.endocrinology-journals.org  2013 Society for Endocrinology
DOI: 10.1530/JOE-13-0285 Printed in Great Britainparticularly important as reducing phosphate (by deplet-
ing the diet in vitamin D or phosphate or by depleting
NaPi cotransporters) and abolishing vitamin D activities
rescue most phenotypes of KlothoK/Kmice (Morishita et al.
2001, Tsujikawa et al. 2003, Hesse et al. 2007, Nakatani
et al. 2009, Ohnishi et al. 2009).
Klotho protein also exists in a soluble form, which can
arise either from a distinct transcript or from ectodomain
shedding of mKlotho (Fig. 1). The large extracellular
domain of the membrane-bound form can be enzy-
matically cleaved (by a- and b-secretases) and released as
‘secreted’ Klotho into blood, urine and cerebrospinal fluid
(CSF). The cleaved 130 kDa extracellular domain may be
the preferably detected Klotho form in extracellular fluids,
as indicated (by the green bars) in Figs 1 and 2 (Imura et al.
2004, Yamazaki et al. 2010). Soluble Klotho (sKlotho)
released into the extracellular spaces can reach and affect
a number of target tissues and processes, including
regulation of hormone and growth factor signalling (e.g.
inhibition of insulin/IGF1) (Kurosu et al. 2005, Wolf et al.
2008), and the regulation of plasma membrane amount
and activity of ion channels and transporters, e.g. toPublished by Bioscientifica Ltd.
AB
Figure 2
Effect of GH-secreting pituitary adenomas on circulating levels of IGF1 and
sKlotho. (A) In the preoperative condition, there is a GH-secreting pituitary
tumour in the pituitary gland. Excessive GH directly acts on the liver
(predominant source of IGF1) and the increased production of IGF1 results
in markedly increased serum IGF1 levels (meanGS.E.M., 0.58G0.03 mg/l).
Excessive GH also results in markedly increased serum sKlotho levels
(4.1G0.4 ng/ml); sKlotho is most likely of renal origin, but the mechanism
(direct/indirect) by which GH excess results in increased release of kidney-
derived sKlotho has not yet been elucidated. sKlotho particles as detected
by the Yamazaki–ELISA (most likely the 130 kDa form) possibly represent
only a tiny fraction of the total amount of sKlotho in the serum. The number
of both IGF1 particles (small yellow circles) and sKlotho particles (green bars,
as in Fig. 1) is dramatically increased, by factors of about 3 and 5 respectively.
(B) Postoperatively, the GH-secreting adenoma has been removed, and
GH action is normal; IGF1 (meanGS.E.M., 0.20G0.01 mg/l) and sKlotho
(0.8G0.1 ng/ml) levels returned towards normal (data from Kohleretal. 2013).
Jo
u
rn
a
l
o
f
E
n
d
o
cr
in
o
lo
g
y
Review C SCHMID and others Growth hormone and Klotho 219 :2 R43
http://joe.endocrinology-journals.org  2013 Society for Endocrinology
DOI: 10.1530/JOE-13-0285 Printed in Great Britainattenuate calciuria. There is an ongoing debate on whether
FGF23 can exert physiologically relevant effects on cells
that do not express functional mKlotho, or do so only to a
level below detection limits for the protein. Experimental
data have suggested that at high doses, FGF23 and 130 kDa
sKlotho, when combined, could allow FGF23 signalling,
e.g. in chondrocytes and osteoblastic cells (Shalhoub et al.
2011, Kawai et al. 2013). Concerning vascular function and
calcification, more recent data in mice and humans
indicate that arterial Klotho expression was low or absent
and did not mediate vascular FGF23 signalling (Lindberg
et al. 2013, Scialla et al. 2013). Currently, sKlotho should
not be labelled as a hormone as cognate receptors have not
been identified so far, in contrast to those known for GH,
IGF1, FGFs and for erythropoietin, 1,25-(OH)2 D and
angiotensin II. In this regard, sKlotho (like renin) could
be considered a renal enzyme rather than a hormone.
Circulating sKlotho can regulate biological processes, e.g.
by (enzymatic) glycan modification. Illustrating an action
on the nephron, sKlotho modifies N-glycan chains of the
epithelial Ca2C channel transient receptor potential cation
channel, subfamily V, member 5 (TRPV5) in the distal
tubule. As a consequence, TRPV5 is retained on the cell
surface and the activity of the ion channel is increased, and
renal calcium loss is decreased (Chang et al. 2005, Cha et al.
2008, Alexander et al. 2009, Huang 2012, Olauson et al.
2012). a-Klotho has been found to be a central player in
calcium (particularly sKlotho) and phosphate (predomi-
nantly mKlotho, FGF23 dependent) homoeostasis, mainly
by acting on the kidneys and the parathyroids (Imura et al.
2007, Nabeshima & Imura 2008, Kuro-o 2010). FGF23
suppresses production of PTH via mKlotho/FGFR–ERK1/2
(Ben-Dov et al. 2007, Krajisnik et al. 2007). Considering its
effects on renal phosphate and calcium handling, a-Klotho
shares phosphaturic effects (proximal tubule) and calcium-
retaining effects (distal tubule) with PTH; however, their
effects on generation of calcitriol are opposite to each other
(stimulation by PTH, inhibition by Klotho). In the
proximal tubule, FGF23 inhibits phosphate reabsorption
by activating FGFR1 in a mKlotho-dependent fashion.
sKlotho could also act as an enzyme (b-glucuronidase-like)
to induce phosphaturia in an FGF23-independent manner;
however, the direct enzyme target (potentially NaPi2a and
NaPi2c) has been less well defined than in the case of TRPV5
(Hu et al. 2010). Disruption of the Klotho gene not only
causes growth arrest, hyperphosphataemia and high
calcitriol but also causes low glucose and insulin levels;
however, whether loss of Klotho directly improves insulin
sensitivity is still unclear (Utsugi et al. 2000, Hesse et al.
2007, Lorenzi et al. 2010). The mice are lean and havePublished by Bioscientifica Ltd.
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differentiation), lower body temperature and less energy
expenditure (Mori et al. 2000, Chihara et al. 2006, Razzaque
2012). Another important role for Klotho, possibly related
to inhibition of insulin/IGF1 signalling, is increased
resistance to oxidative stress, which may contribute to
the anti-ageing properties of Klotho (Yamamoto et al.
2005). Along this line, Klotho protein exerts protective
effects, e.g. Klotho protein treatment attenuated cisplatin-
induced reactive oxygen species generation. Thereby, it
possibly helped to prevent reduction in cell viability in
response to this ototoxic drug in an auditory cell line (Park
et al. 2012). On the other hand, Klotho sensitized lung
cancer cells to cisplatin, apparently via the PI3K/PKB
pathway (Wang et al. 2013).
CP epithelial cells, besides renal tubular cells, express
the highest levels of Klotho but they have been studied less
often than kidney cells. Imura et al. (2007) were the first to
address potential roles of Klotho in this tissue and reported
on the action of a-Klotho on NaC/KC ATPase activity and
transcellular calcium transport. It appears likely that
Klotho in CP cells contributes to regulation of compo-
sition and homoeostasis of CSF similarly as the kidneys
contribute to the homoeostasis and regulation of plasma
composition; therefore, CP has been considered as the
‘kidney’ of the brain. Recently, a molecular character-
ization employing a combination of transcriptomics and
high-resolution tandem mass spectroscopy-based proteo-
mics methods was carried out (in rats) to gain insight into
CP function (Sathyanesan et al. 2012). A validation of the
findings at the mRNA and protein level was done by in situ
hybridization and immunohistochemistry. The close
relationship between the transcriptome and proteome
profiles from the CP and the kidney tubules was a main
finding; physiological parallels between CP and renal
tubuar cells include high energy (and high blood flow)
requirement and highly regulated pumps and transporter
activities in both tissues. In addition, strong expression of
Klotho was confirmed, and co-localization with transthy-
retin (an excellent CP marker) in CP was demonstrated
(Kuro-o et al. 1997, Li et al. 2004, Sathyanesan et al.
2012). Chronic unpredictable stress reduced expression of
Klotho in CP of their rats, as Ohyama found that acute
inflammatory stress decreased renal Klotho expression
(Ohyama et al. 1998, Sathyanesan et al. 2012).
Soon after discovery of the Klotho-deficient mouse, it
was found that Klotho protein protects against endothelial
dysfunction (Saito et al. 1998, 2000). Klotho contributes to
maintenance of endothelial function and NO production
via cAMP and calcium channel activation, upregulation ofhttp://joe.endocrinology-journals.org  2013 Society for Endocrinology
DOI: 10.1530/JOE-13-0285 Printed in Great Britainthe mitogen-activated kinase pathway, and increases stress
tolerance, decreases oxidative damage, apoptosis and
senescence of endothelial cells (Ikushima et al. 2006,
Rakugi et al. 2007, Kusaba et al. 2010, Maekawa et al.
2011, Carracedo et al. 2012).
Germ line mutations or polymorphisms in Klotho do
not obviously predispose to the development of neo-
plasms, and there is no evidence for an increased incidence
of malignancies in Klotho-deficient mice. Nevertheless,
Klotho can be viewed as a potential tumour suppressor, e.g.
in breast, pancreatic, lung and renal cancer (Wolf et al.
2008, Chen et al. 2010, Abramovitz et al. 2011, Zhu et al.
2013). Intratumoral Klotho decline correlates with cancer
progression, tumour size, TNM stage and nuclear grade in
renal cell carcinoma, and with enhanced activation of the
PI3K/PKB pathway (Zhu et al. 2013). Functional loss of
Klotho due to epigenetic silencing was found to promote
tumour progression in a variety of cancers.
Inhibition of Wnt signalling may play a role in the
senescence-suppressing and renal fibrosis inhibitory effects
of Klotho (Liu et al. 2007, Doi et al. 2011, Satoh et al. 2012,
Sugiura et al. 2012, Zhou et al. 2013); TGFb appears to
activate b-catenin via suppression of Klotho. sKlotho via its
Kl1 domain blocks Wnt-triggered activation and nuclear
translocation of b-catenin and thereby protects the kidneys
from developing fibrosis in response to injury (Zhou et al.
2013). sKlotho attenuates IGF1 signals in the compensa-
tory renal hypertrophy following uninephrectomy
(Nagasu et al. 2011). Decreased serum sKlotho was
associated with enhanced cyst growth in patients with
autosomal dominant polycystic kidney disease (Pavik et al.
2012). As described for IGF1/PI3K/PKB signalling, sKlotho
may also contribute to apoptosis induction and cell growth
inhibition by decreasing the activity of the Wnt- b-catenin
signalling pathway (Chen et al. 2012).
Gene delivery of Klotho could influence several
pathophysiological phenotypes of Klotho mice, including
improvement of vascular calcification (Shiraki-Iida et al.
2000), protection against endothelial dysfunction (Saito
et al. 2000) and preventing progression of angiotensin II-
induced or hypertensive renal damage (Mitani et al. 2002,
Wang & Sun 2009). More recently, administration of
recombinant sKlotho protein to KlothoK/Kmice was found
to suppress accelerated ageing (Chen et al. 2013b).Human pathologies due to deficient or excessive Klotho?
Years before immunoassays became available, genetic
studies were performed. Arking et al. (2002) reported an
association of human ageing with a functional variant ofPublished by Bioscientifica Ltd.
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found to have reduced cognitive abilities (Deary et al.
2005). More recently, a functional variant of Klotho was
found to be associated with early-onset ischaemic stroke
(Majumdar et al. 2010). A 13-year-old girl with a
remarkable phenotype of hyperphosphataemia, and soft
tissue and vascular calcification, ‘tumoral’ calcinosis, was
found to harbour a homozygous missense (H193R)
mutation in the Klotho gene. Hyperphosphataemia was
consistent with renal FGF23 resistance, as Klotho
mutations are expected to prevent complex formation
with FGF23 (functionally defective receptors), and lead to
decreased FGF23 signalling: FGF23 was indeed markedly
elevated (familial ‘tumoral’ calcinosis was a known
phenotype caused by inactivating mutations in FGF23 or
GALNT3, i.e. diseases caused by defective ligand had been
described before). Hyperparathyroidism was proposed to
be caused by a lack of an a-Klotho-dependent inhibitory
effect of FGF23 on PTH production, although it should
be noted that a-Klotho could also affect PTH secretion
directly (without FGF23), by increasing cell surface
NaC–KC-ATPase activity (Ichikawa et al. 2007, Imura
et al. 2007). Another exceptional case was reported, with
a translocation adjacent to a-Klotho gene, causing
markedly increased circulating a-Klotho (and FGF23)
level, resulting in hypophosphataemia (with rickets) and
hyperparathyroidism (Brownstein et al. 2008). In animals,
circulating a-Klotho per se may induce FGF23 production
and phosphaturia (Smith et al. 2012), and so may
antibodies activating FGFR1 (Wu et al. 2013).
sKlotho is released into the circulation, and its plasma
half-life has been estimated to be about 20–30 min by
Imura. sKlotho can be detected by a recently developed
and commercially available sandwich ELISA (Yamazaki
et al. 2010; Table 1). Levels of sKlotho decrease with age in
healthy subjects and are inversely related to mortality in
the elderly (Semba et al. 2011). High levels of sKlotho were
found in human umbilical cord blood (Ohata et al. 2011,
Siahanidou et al. 2012). The placenta is known to produce
sKlotho and may account for these high levels. However,
except for the neonatal period, the kidneys appear to be
the major source of sKlotho in sera of human subjects.
Accordingly, serum sKlotho decreased by about
40% following nephrectomy in living donors (Akimoto
et al. 2013). So far, there is no well-established reference
range for serum sKlotho. In our Zu¨rich area, the median
value of healthy adult subjects is around 0.6 ng/ml and,
therefore, somewhat lower than previously reported by
Japanese and Italian authors using the same assay
(Yamazaki et al. 2010, Semba et al. 2011, Akimoto et al.http://joe.endocrinology-journals.org  2013 Society for Endocrinology
DOI: 10.1530/JOE-13-0285 Printed in Great Britain2012, Neidert et al. 2013, Pavik et al. 2013). Interestingly,
the Italian authors found that low circulating sKlotho
levels in elderly adults are not only associated with
increased mortality but also associated with poor muscle
strength and disability in activities of daily living (Semba
et al. 2011, 2012, Crasto et al. 2012).
It should be mentioned that many uncertainties still
exist when assessing sKlotho levels, as the identity of the
detected molecules is not always clear (see also Figs 1
and 2). In fact, in 2004, Xiao et al. reported on a polyclonal
antibody raised in rabbits against the C-terminal of human
secreted Klotho protein (amino acids 290–549). It could be
used for western blotting to detect mainly a 60 kDa
protein and for an ELISA to measure sKlotho in human
serum; sKlotho was found to decrease with age with this
particular assay (Xiao et al. 2004).
The ImmunoBiological Laboratories (IBL, Fujioka,
Japan) ELISA as developed by Yamazaki and the time-
resolved fluorescence immunoassay (Cusabio, Wuhan,
China) assays have recently been directly compared in a
Danish study where considerable differences became
evident (Pedersen et al. 2013). The IBL ELISA utilizes two
monoclonal antibodies that may detect and measure one
larger form of (‘intact’, full-length shedded) Klotho. On
the other hand, the Cusabio assay (using mouse mono-
clonal antibody-precoated plates and goat polyclonal
antibodies of unknown epitope specificity for detection)
may recognize additional, shorter forms (65 kDa and
possibly other forms) that may be much more abundant
(Matsumura et al. 1998). As mentioned, the IBL assay has
been used quite often lately (Table 1), whereas the Cusabio–
ELISA has been validated just recently in studies performed
in the USA and Denmark (Devaraj et al. 2012, Pedersen et al.
2013). In their review, Hu et al. (2013) estimated plasma
concentrations of sKlotho in the range of 10–50 nM, which
would be much higher than what is measured by the
Yamazaki assay (Yamazaki et al. 2010).
CKD can be viewed as a state of Klotho deficiency. As
the kidney is the primary source and a major target of
Klotho, the focus of Klotho research has been on
nephrology, apart from basic and ageing research.
Although renal expression of the Klotho gene and urinary
Klotho levels have been found to be decreased in renal
disease (Koh et al. 2001, Hu et al. 2011), it currently
remains controversial whether plasma sKlotho is a useful
biomarker for kidney disease (Sugiura et al. 2011, Pavik
et al. 2012, 2013, Kim et al. 2013, Seiler et al. 2013). FGF23
may give a much better readout than sKlotho, as the
hormone released by bone in response to kidney disease
appears to quite reliably reflect renal resistance to FGF23.Published by Bioscientifica Ltd.
Table 1 Soluble serum Klotho levels in healthy human subjects as assessed by IBL ELISA
Author/year n Subjects Age (years) Sex (m/f)
Klotho levels
(pg/ml) Comments
Akimoto et al.
(2013)
10 Living kidney
donors
64G9 4/6 910 (median); 755–1132
(IQR)
The kidneys seem to be the
major source of serum
sKlotho
Amitani et al.
(2013)
11 Healthy 21G1
(S.E.M.)
0/11 1392G145 (S.E.M.GS.E.) Klotho levels are lower in
patients with anorexia
nervosa and patients with
obesity than in normal
weight controls
Crasto et al.
(2012)
802 Elderly O65 357/445 689 (mean); 238 (S.D.) Low serum Klotho is associ-
ated with ADL disability
Neidert et al.
(2013)
26 Healthy 39G8 15/11 596 (median); 506–734
(IQR)
Serum Klotho is excessively
elevated in patients with
untreated acromegaly
Pedersen et al.
(2013)
120 Healthy 40 (19–66)
median
(range)
58/62 472G137 (meanGS.D.) Different immunoassays
recognize distinct forms of
sKlotho
Pavik et al.
(2012)
20 Healthy 32G6 12/8 1200G385 (meanGS.D.) Low serum sKlotho is associ-
ated with cyst growth and
low phosphaturic activity
of FGF23 in ADPKD
Pavik et al.
(2013)
21 Healthy 48G8 9/12 600 (median); 429–862
(IQR)
Serum Klotho decreases in
advanced CKD
Semba et al.
(2011)
1023 Elderly 73 (69–79)
median
(IQR)
564/459 676 (median); 530–819
(IQR)
Klotho is inversely related to
CVD risk
Semba et al.
(2011)
804 Elderly O65 354/450 697G325 (meanGS.D.) Serum sKlotho is suggested
as an independent predic-
tor of all-cause mortality
Sugiura et al.
(2011)
10 Healthy 20–44 NA 404G87 (meanGS.D.) Increased serum sKlotho is
suggested as a renopro-
tective factor in CKD
Yamazaki et al.
(2010)
181 142 healthy adults
(39 children)
61G19
(7G8)
66/76
(23/16)
562G146 (meanGS.D.)
952G282 (meanGS.D.)
Serum Klotho is inversely
related to age and creati-
nine
ADL, activities of daily living; ADPKD, autosomal dominant polycystic kidney disease; CKD, chronic kidney disease; CVD, cardiovascular disease;
eGFR, estimated glomerular filtration rate; FGF23, fibroblast growth factor 23; IBL, ImmunoBiological Laboratories Co. Ltd.; IQR, interquartile range.
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(classical) target effects of hormones adapting to a
resistance induced by Klotho deficiency: FGF23 excess
may (not result in hypophosphataemia but) induce left
ventricular hypertrophy in a Klotho-independent manner
(Faul et al. 2011).
As reported by Imura et al. (2004), sKlotho can be
found not only in serum and urine but also in CSF.
Interestingly, levels of sKlotho are quite high in CSF and in
urine; CP and kidney as Klotho-expressing sites may
account for these findings. CSF Klotho levels as measured
by immunoassay have not been reported in the literature,
but data for urine are available and suggest that urine
Klotho is linked to renal function (Akimoto et al. 2012).
Over the past 6 months (January–June 2013), we have also
started to assess CSF and urine samples for sKlotho.
According to these preliminary data, concentrations ofhttp://joe.endocrinology-journals.org  2013 Society for Endocrinology
DOI: 10.1530/JOE-13-0285 Printed in Great BritainsKlotho are similar or slightly higher in CSF than in serum:
sKlotho was 888 (595–1319) pg/ml (median (range)) in
CSF (nZ9) vs 557 (255–1017) pg/ml in the corresponding
sera. This is remarkable, given that the total protein
concentration is two orders of magnitude lower in CSF
than in plasma and serum. Despite samples obtained from
quite distinct patients (none of them, with acromegaly)
for CSF analysis, we found a narrow concentration range
in CSF when compared with serum. This could suggest
that Klotho levels are maintained within a certain limit
within this compartment. Klotho may be biologically
active and play an important role in brain and regulating
functions of CSF (Imura et al. 2004, 2007). It is currently
unknown whether changes in CSF Klotho reflect and/or
contribute to neurological and neurosurgical disorders.
As mentioned earlier, urinary Klotho concentrations
have been measured in patients with renal disease. We hadPublished by Bioscientifica Ltd.
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levels in patients with acromegaly.
Urinary Klotho concentrations remained below the
detection limit in unconcentrated spot urine samples of
nine patients cured from acromegaly and of six patients
with non-functioning pituitary adenomas but detectable
in nine patients with newly diagnosed acromegaly, which
suggests that increased urinary sKlotho could have a high
positive predictive value for the diagnosis of the disease
(Fig. 3). However, technical issues need to be addressed
and the sensitivity of the analysis refined before urinary
Klotho can be considered a useful marker for estimating
GH excess in individual patients.
Based on sequence similarity with the Klotho gene,
b-Klotho was identified, and the former (the founder of
the family) occasionally renamed a-Klotho (Ito et al. 2000).
g-Klotho was identified as another, functionally more
remote member of the family, which is expressed
particularly in kidneys, adipose tissue and eyes (Ito et al.
2002). a-Klotho protein shares 41% amino acid sequence
identity with b-Klotho. b-Klotho is expressed predomi-
nantly in the liver and white adipose tissue, i.e. in tissues
that are targets of FGF19 and FGF21 (endocrine FGFs, likeSerum sKlotho (pg/ml)
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Figure 3
Concentrations of soluble Klotho (sKlotho) in serum and urine of patients
with acromegaly. Concentrations of Klotho were assessed by ELISA in serum
and urine samples (spots, obtained the same time point as blood) from
patients with pituitary adenomas (between 1/2013 and 6/2013). Each point
represents an individual; filled circles, active (newly diagnosed, untreated)
acromegaly (nine patients, three females); empty circles, successfully
(by transsphenoidal surgery) treated acromegaly (as confirmed by normal
IGF1 and GH suppressible to !1 ng/ml during oGTT; nine patients, three
females) and filled triangles, clinically non-functioning pituitary adenoma
(six patients, three females). Note that both the x-axis (serum sKlotho
(pg/ml)) and y-axis (urine Klotho, expressed in pg sKlotho/mmol creatinine)
are drawn on logarithmic scales. Patients with active acromegaly have
higher serum and urinary sKlotho levels than patients without active
acromegaly; in urine, sKlotho was readily detectable (concentration above
the detection limit of the ELISA) only in samples from patients
with acromegaly.
http://joe.endocrinology-journals.org  2013 Society for Endocrinology
DOI: 10.1530/JOE-13-0285 Printed in Great BritainFGF23), and b-Klotho was found to work as co-receptor
for FGF19 and FGF21 signalling. In mammals, Klothos
(a and b) are type 1 transmembrane proteins that function
as obligatory cofactors for signalling of all known,
vertebrate specific, hormone-like (‘endocrine’) FGFs:
FGF15/FGF19 (enterocyte), 21 (hepatocyte) and 23 (osteo-
cyte). The (FGF) ligand, the (FGF) receptor and its (Klotho)
co-receptor usually define the specificity of the endocrine
actions (Tomiyama et al. 2010); however, in artificial
experimental settings, promiscuity of signalling is
observed, for instance by FGF23 mutants with an ability
to activate FGFR signalling through both a- and b-Klotho
(Wu et al. 2012), or with antibodies activating FGFR1,
which may act in a FGF21-like manner (requiring b-Klotho
on target cells) or in a FGF23-like manner (requiring
a-Klotho on target cells), to induce hypophosphataemia
(Wu et al. 2013).Role for a-Klotho in acromegaly?
Luft and colleagues recognized that acromegaly had a
marked impact on renal function (Ikkos et al. 1956).
Administration of GH increased renal GFR and tubular
phosphate reabsorption (Corvilain et al. 1962, Bianda et al.
1997). The latter effect of GH cannot be explained by a
deficiency of known classical phosphaturic hormones
such as PTH and FGF23. Reviewing old data on GH, IGF1
and phosphate transport, it is important to realize that
stimulatory effects of GH on renal phosphate reabsorption
in adult humans have been repeatedly found in vivo. A
stimulatory effect of IGF1 on phosphate uptake can be
documented in most cultured cells, but the finding of
phosphate uptake stimulation by IGF1 in vitro has not
been shared by GH, and the claim that IGF1 is mediating
this effect of GH may have been premature (Quigley &
Baum 1991, Zoidis et al. 2004). Maximal tubular phos-
phate reabsorption per GFR was raised by GH but not by
IGF1 compared with saline; thus, IGF1 does not mimic
(and possibly not mediate) the TmP/GFR raising effect of
GH on renal phosphate reabsorption despite comparable
effects on GFR (Bianda et al. 1997, Schmid & Meili 2000).
Acromegaly has unique biochemical and endocrine
features; it leads to high serum phosphate and FGF23 levels
despite enhanced GFR, as well as to insulin resistance (IR)
and hyperglycaemia (Table 2). These characteristics are
distinct from those observed in more common conditions
such as renal failure and type 2 diabetes: high phosphate
levels cannot be attributed to decreased GFR, and IR and
hyperglycaemia are not caused by increased visceral fat.
Although levels of phosphate and FGF23 are high inPublished by Bioscientifica Ltd.
Table 2 Parameters and phenotypes characterizing GH excess,
Klotho deficiency and CKD
Parameter GH excess
Klotho
deficiency CKD
Growth [[ YY Y
Lifespan Y YYY YY
Energy expenditure [ Y 4Y
Glucose, IR [[ YY 4[
Creatinine Y [ [[[
eGFR [ Y YYY
1,25-(OH)2 vitamin D [[ [[[ YY
Phosphate [ [[[ [[
FGF23 [ [[[ [[[
Calcium 4[ [[ 4Y
PTH 4 4Y [[
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate;
IR, insulin resistance.
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FGF23 (usually inhibiting renal phosphate reabsorption
and calcitriol production) and phosphate tend to be high
despite increased GFR, in keeping with a condition of renal
FGF23 resistance (Table 2; Ito et al. 2007).
Longer lasting excessive secretion of GH by a pituitary
adenoma results in premature death, mainly due to an
increased risk for cardiovascular disease. In human adults,
GH (but not IGF1) increases the set points of plasma
glucose and phosphate, and both IR and elevated serum
phosphate are associated with increased mortality in the
general population.
As Klotho levels may relate to FGF23 resistance and IR
(or high phosphate and glucose respectively) in acrome-
galy, we measured sKlotho in sera of patients before and
after transsphenoidal surgery. Removal of the pituitary
adenoma led to the expected decrease in GH and IGF1.
sKlotho was markedly increased in relation to GH excess
and declined towards normal levels after surgery (Sze et al.
2012); differences in sKlotho before and after surgery were
at least as pronounced as IGF1 (Sze et al. 2012, Kohler et al.
2013; Fig. 2). While sKlotho was elevated in sera of patients
with active acromegaly, this did not hold true for patients
with clinically non-functioning pituitary adenomas
(Neidert et al. 2013). In the latter study, it was shown that
sKlotho fell at least as quickly as IGF1 after surgery.
Moreover, the pituitary adenomas were analysed for Klotho
by immunohistochemical staining. It was found that the
rise in serum a-Klotho is not explained by increased
pituitary (adenoma) Klotho expression, but rather by
increased pituitary GH secretion and possibly due to a
systemic action of GH. However, renal biopsies to check for
changes in amounts of mKlotho were not performed.http://joe.endocrinology-journals.org  2013 Society for Endocrinology
DOI: 10.1530/JOE-13-0285 Printed in Great BritainAs sKlotho may reflect activity of GH-producing
adenomas, it could serve as an additional serum marker
in the long-term follow-up of acromegalic patients.
Overall, when assessing patients with GH-producing
adenomas, we observed concomitant and parallel changes
in serum IGF1 and sKlotho over time in a given individual
patient, and levels of sKlotho and IGF1 appeared to be
similarly dependent on GH (Sze et al. 2012, Kohler et al.
2013). A remarkable difference was found with regard to
gender; for a given GH (excess) status, IGF1 tended to be
higher in males whereas sKlotho levels were higher in
females; more detailed analysis revealed that oestrogens
accounted for lower IGF1 in (premenopausal) women,
but not for the higher sKlotho; overall, GH was by far
the strongest predictor of both sKlotho and IGF1 (L Sze,
MC Neidert, RL Bernays & C Schmid, 2013, unpublished
observations).
In human adults, GH deficiency results in a more or less
characteristic but much less obvious phenotype than in
children (dwarfism); hypoglycaemia and hypophosphatae-
mia are not obvious features. In the study by Neidert,
sKlotho did not appear to be particularly low in patients
with GH deficiency. It remains to be tested whether
sKlotho levels are decreased in patients with GH deficiency,
and whether GH treatment results in increasing serum
sKlotho levels. Considering sKlotho as a GH-dependent
serum protein, a response to GH replacement might be
anticipated, but in view of kidney function and phosphate
homoeostasis, differences in sKlotho are possibly smaller
between healthy adults and patients with GH deficiency
when compared with those with GH excess.GH and Klotho
As mentioned, Klotho mutant (KlothoK/K) mice exhibit
growth retardation after weaning and premature death.
Electron microscopic examination of GH-producing cells
in pituitary glands revealed a reduction in GH granules.
Growth retardation was described in the original 1997
paper (Kuro-o et al. 1997). As it has not been known
whether growth retardation in Klotho mutant mice is
related to loss of GH function, Kashimada et al. examined
whether treatment with GH could rescue retardation of
growth. At the end of 3 weeks of treatment with human
GH, body weight was not increased in Klotho mutant
(KlothoK/K) mice in contrast to WT mice. Growth
retardation in Klotho mutant mice is therefore resistant
against GH treatment, and GH deficiency is not the
cause of growth arrest in KlothoK/K mice (Kashimada
et al. 2002).Published by Bioscientifica Ltd.
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lifespan by an excess in the anabolic peptide hormones
GH, IGF1 and insulin. These data are difficult to accept not
only by people abusing such hormones but also for the
medical community, including endocrinologists. With
regard to life expectancy, apparent contradictions con-
cerning the action of GH should be considered. GH has
generally been associated with positive attributes of
adolescence and youth, such as growth, health, muscle
mass and well-being, yet the bulk of scientific evidence
suggests that signalling through GH, IGF1 and insulin
receptors is related to a shortened lifespan in adults
(Berryman et al. 2008, Junnila et al. 2013). It is currently
difficult to estimate whether high sKlotho levels can
attenuate insulin and IGF1 receptor signalling in vivo,
e.g. in patients with acromegaly. In their overviews,
Kopchick and colleagues have underlined the importance
of GH, IGF1 and insulin signalling in regulating lifespan;
according to our view, not only the GH–IGF1 axis and IR
but also FGF23 resistance and hyperphosphataemia in the
context of the GH–Klotho axis deserve more attention.
Concerning the renal effects of GH, several aspects of
Klotho can be considered (Table 2). Apparently, GH clearly
opposes the effects attributed to mKlotho and its essential
role in mediating FGF23-induced renal phosphate loss and
FGF23-mediated inhibition of calcitriol production
(Bianda et al. 1997). Hypervitaminosis D due to over-
expression of CYP27B1 is central to the phenotypes of
a-mKlotho and FGF23 deficiency, and hypovitaminosis D
due to suppression of CYP27B1 is a central phenotype
of FGF23 transgenic mice. With regard to vitamin D
metabolism, GH increases vitamin D activation in humans
and experimental animals and can, therefore, be
considered as an antagonist of FGF23 action mediated
via the FGFR/a–mKlotho complex (Bianda et al. 1997,
1998, Zoidis et al. 2002). GH stimulates 25-hydroxy-
vitamin D 1a-hydroxylase (CYP27B1) mRNA and mark-
edly down regulates 24-hydroxylase (CYP24A1) mRNA
expression; the former enzyme favours activation and the
latter degradation of active vitamin D (Zoidis et al. 2002).
As mentioned in the previous section, the high levels of
phosphate and calcitriol together with increased FGF23
suggest a state of renal FGF23 resistance in patients with
acromegaly (Ito et al. 2007, Sze et al. 2012). It is, therefore,
conceivable that GH induces functional impairment of
the FGF23–mKlotho signalling pathway in proximal
tubular cells.
On the other hand, GH shares the effects of sKlotho on
the distal convoluted tubule to attenuate calciuria.
However, as calcium, calcitriol and GFR tend to behttp://joe.endocrinology-journals.org  2013 Society for Endocrinology
DOI: 10.1530/JOE-13-0285 Printed in Great Britainincreased in patients with acromegaly, increased calcium
reabsorption in the distal convoluted tubule may be
masked (acromegalic patients tend to have fasting
hypercalciuria). sKlotho may not only account for an
increased calcium loss when deficient (as in diabetic
nephropathy) but also for attenuation of renal calcium
loss or when present in excess (as in acromegaly) (Asai et al.
2012, Kamenicky et al. 2012).
Concerning parathyroid function, findings reported
from patients with acromegaly have been variable,
especially in studies of drug-treated patients (White et al.
2006, Kamenicky et al. 2012). More consistent data from
patients with adenectomy-treated acromegaly suggest that
PTH levels remain essentially unchanged when the
preoperative condition is compared with the postopera-
tive condition (Lund et al. 1981, Takamoto et al. 1985).
Likewise, high-dose short-term GH treatment in a more
controlled setting of healthy volunteers or GH-deficient
patients did not alter PTH levels, despite significant
increases in 1,25-(OH)2 D and a trend for increased
calcium levels, as observed in acromegaly (Lund et al.
1981, Takamoto et al. 1985, Bianda et al. 1997, Bianda et al.
1998). Given the fact that in acromegalic patients,
consistently calcium tends to be high in parallel with
increased calcitriol and FGF23 values, but in the presence
of unchanged PTH, it is likely that inappropriate feedback
inhibition of PTH occurs (Table 2). One potential
explanation would be that FGF23 action on PTH secretion
is impaired possibly by a functional mKlotho deficiency
(as proposed for kidneys; Ben-Dov et al. 2007, Krajisnik
et al. 2007).
Considering effects of GH on the endothelium, it
appears that some are potentially favourable for cardio-
vascular health whereas others such as IR, hyperglycaemia
and hyperphosphataemia negatively impact on endo-
thelial function. Ageing is associated with a decrease in
GH, endothelial function (nitric oxide synthase activity
and abundance of eNOS), cardiovascular and renal health.
GH deficiency has been associated with impaired endo-
thelial function, and GH replacement could improve
endothelial function (Boger et al. 1996, Evans et al.
2000). As mentioned earlier, Klotho protein protects
against endothelial dysfunction and exerts several
beneficial (anti-senescence) effects on endothelial cells,
including some mediated via the MAPK pathway (Saito
et al. 1998, 2000, Ikushima et al. 2006, Kusaba et al. 2010,
Maekawa et al. 2011, Carracedo et al. 2012). However, it is
currently unknown whether Klotho is involved
(a downstream effector or mediator) in the effects of GH
on the endothelium.Published by Bioscientifica Ltd.
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recognized that hypertension and hyperglycaemia/
diabetes contribute to the increased cardiovascular disease
risk in these patients. Phosphate has been considered less
as a risk factor, although more recent data suggest that
hyperphosphataemia and possibly phosphate intake are
associated with increased cardiovascular risk, even in
the absence of established renal disease (Tonelli et al.
2005, Dhingra et al. 2007, Foley 2009, Shuto et al. 2009,
Ellam & Chico 2012, Osuka & Razzaque 2012, Yamamoto
et al. 2013). Excessive phosphate not merely favours
ectopic (including media) calcification but also impairs
endothelial function (e.g. NO synthesis, annexin II
regulation, etc.) (Lau et al. 2011, Di Marco et al. 2013).
In acromegaly, it may be that potentially beneficial effects
of GH and Klotho on endothelial function and NO
synthesis are outweighed by IR and hyperphosphataemia,
so that there is a net increase in cardiovascular risk.
GH-induced high phosphate levels may make sense in
the context of growth, but it appears likely that they are
harmful in adulthood.
The findings of remarkably high serum sKlotho
levels in patients with active acromegaly are difficult to
interpret, and additional data are required. The biological
meaning remains unclear, and currently, it is uncertain
whether changes in Klotho turnover account for the high
threshold of renal phosphate reabsorption and FGF23
resistance with GH excess; moreover, the mechanisms by
which acromegaly leads to excess sKlotho remain to be
elucidated. One can speculate about several mechanisms;
GH may increase Klotho gene expression in kidneys (and
other sites). Soluble forms of a-Klotho could be generated
by alternative splicing of its transcript but they could also
result from proteolytic cleavage of the transmembrane
form by secretases into various body fluids. Two members
of the ‘A Disintegrin and Metalloproteinase’ (ADAM)
family, ADAM10 and ADAM17 (a-secretases), and b-site
amyloid precursor protein-cleaving enzyme 1 (BACE1)
(b-secretase), have been suggested as responsible enzymes
(Chen et al. 2007, Bloch et al. 2009, Saftig & Reiss 2011).
The high sKlotho levels in acromegalic patients do not
necessarily reflect a high level of cell mKlotho (in the
kidneys, the parathyroids and elsewhere). A discrepancy
between renal mKlotho and sKlotho has been discussed
for experimental settings, and it was considered that
increased sKlotho could be caused by accelerated shedding
of Klotho without corresponding changes in mKlotho
expression (Lau et al. 2012). In acromegaly, FGF23
resistance cannot be explained by high sKlotho per se,
unless sKlotho is elevated at the expense of mKlotho, whichhttp://joe.endocrinology-journals.org  2013 Society for Endocrinology
DOI: 10.1530/JOE-13-0285 Printed in Great Britainserves as a co-receptor for FGF23. Formally, resistance to
FGF23 may be caused by decreased expression of the
Klotho–FGFR1 complex. This should be investigated at
the level of the kidneys and the parathyroids, and this
has indeed been addressed in patients with CKD where
parathyroids were studied to find the basis for parathyroid
resistance to FGF23 (Galitzer et al. 2010, Komaba et al.
2010, Krajisnik et al. 2010). Similar investigations have
not been performed with tissues from patients with
acromegaly. According to our hypothesis, the activity
of secretases (shedding the ectodomain from the integral
mKlotho) may be increased in acromegaly, either
directly by GH or indirectly by factors or by proteolytic
activity induced by GH. As previously mentioned, GH
has a proteolytic activity on other systems, as it induced
an IGFBP3-proteolytic activity in vivo in rats; moreover,
GH stimulates the mRNA expression not only of the
cytochrome P450 enzyme CYP27B1 involved in the
production of active vitamin D (calcitriol) but also
the phex mRNA that encodes for an endopeptidase
important in phosphate homoeostasis (Rutishauser et al.
1993, Zoidis et al. 2002). Increased mKlotho-proteolytic
activity could result in deficient mKlotho and impaired
FGF23 signalling, thereby explaining FGF23 resistance;
the enhanced enzymatic clipping of the extracellular
Klotho domain would lead to an excess in sKlotho
contributing to channel and transporter regulation, to
attenuation of calciuria, growth factor signalling and IR.
Thus far, it has not been studied whether GH
stimulates the production of Klotho. It will be of interest
to see whether GH increases serum levels of sKlotho in
GH-deficient subjects and to see whether GH influences
expression of Klotho at the mRNA level and whether it
regulates the abundance of mKlotho in tissues and sKlotho
in extracellular spaces. Such studies have been performed
in experimental animals with calcium- and phosphate-
regulating hormones (PTH, calcitriol, FGF23; increasing
renal expression and serum levels in rats) but not with
GH (Takenaka et al. 2013).
As mentioned earlier, b-Klotho is important as a
co-receptor for FGF19 and FGF21 signalling. GH induces
hepatic production of FGF21, apparently through a
mechanism dependent on lipolysis in adipocytes. In this
context, it is interesting to know that GH stimulates
lipolysis especially in the state of fasting (when insulin is
low). FGF21, in turn, inhibits GH action on chondrocytes
directly at the growth plate; FGF21 may also mediate GH
resistance in anorexia nervosa as illustrated by high GH
and low IGF1. Taken together, there are not only multiple
interacting targets between GH and a-Klotho in calciumPublished by Bioscientifica Ltd.
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and b-Klotho pathways are closely linked in order to
regulate fuel metabolism, at both afferent and efferent
parts of endocrine loops. So far, due to lack of appropriate
assays to measure sb-Klotho and sa-Klotho, data lag far
behind basic research in this field.Conclusions
There is increasing interest in the field of GH and Klotho
and their mutual interaction. Many questions can be
addressed by both basic and clinical studies. Both IGF1
and sKlotho are relatively abundant in the circulation;
both of them are regulated by GH (Sze et al. 2012, Hu et al.
2013, Neidert et al. 2013). In the case of IGF1, there is fairly
good evidence that it mediates some actions of GH and
that there is a negative feedback at the pituitary level.
a-Klotho expression can also be documented in the
pituitary gland (Kuro-o et al. 1997, Li et al. 2004, Neidert
et al. 2013), and FGF23 administration to rats increased
early growth response-1 (Egr1) mRNA levels in the
pituitary as it did in the kidney and parathyroids (Urakawa
et al. 2006); however, a feedback action of FGF23 and
Klotho on the pituitary GH secretion has not been
described so far. There are no data available that show
how FGF23 or Klotho may mediate GH actions.
In acromegaly, IGF1 (predominantly liver-derived),
a marker and mediator of GH action, is increased, as is
sKlotho (predominantly kidney-derived), a marker of
GH-producing pituitary adenomas. Further observations
and experiments should allow more insight, e.g. as to
whether generation of sKlotho could mediate selected
actions of GH, causing FGF23 resistance, hyperphospha-
taemia, possibly contributing to IR and hyperglycaemia,
contributing to improved endothelial function, increased
energy expenditure and decreased life expectancy.Declaration of interest
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